Palabras clave
Penfigoide ampolloso
Inhibidores DPP4
Categorías
Cómo citar
Resumen
El penfigoide ampolloso es una entidad clínica que ha sido descrita asimismo como un efecto adverso asociado al uso de determinados fármacos. Resulta fundamental realizar un diagnóstico diferencial exhaustivo y establecer las posibles etiologías con el objetivo de instaurar un tratamiento adecuado y lograr la resolución del cuadro clínico. Su posible asociación con procesos neoplásicos también ha sido objeto de estudio, sin embargo no existe hasta el momento evidencia concluyente más allá de la procedente de estudios observacionales y revisiones sistemáticas. En los casos de penfigoide ampolloso inducido por fármacos, la respuesta al tratamiento con corticosteroides suele ser favorable. En caso de resistencia se podrían emplear anticuerpos, preferidos sobre terapia inmunosupresora. Se presenta una revisión actualizada de la literatura, ilustrada mediante un caso clínico en el que han podido estar implicados más de un agente farmacológico, como son la inmunoterapia basada en un anticuerpo monoclonal anti-PD1 y un antidiabético oral inhibidor de la dipeptidil-peptidasa 4. Su reconocimiento temprano es importante de cara al pronóstico de la toxicidad.
Referencias
Yamagami J. Recent advances in the understanding and treat- ment of pemphigus and pemphigoid. F1000Res. 2018 Aug 30;7:1360. doi:10.12688/f1000research.14474.1.
Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol. 2017;18(4):513–528. doi:10.1007/s40257-017-0264-2.
Merli M, Accorinti M, Romagnuolo M, Marzano AV, Di Zen- zo G, Moro F, Antiga E, Maglie R, Cozzani E, Quaglino P, et al. Autoimmune bullous dermatoses in cancer patients trea- ted by immunotherapy: a literature review and Italian multi- centric experience. Front Med (Lausanne). 2023;10:1208418. doi:10.3389/fmed.2023.1208418.
He MJ, et al. Relationship between bullous pemphigoid and malignancy: systematic review and meta-analysis. J Derma- tol. 2024;51. doi:10.1111/1346-8138.17100.
Czarnecka D, et al. Paraneoplastic bullous pemphigoid in as- sociation with squamous cell carcinoma of the lung. Forum Dermatologicum. 2025;11(1):37–40. doi:10.5603/fd.104206.
Li J, Zuo YG, Zheng HY, Qiu NS. Association between bu- llous pemphigoid and internal diseases. J Dtsch Dermatol Ges. 2013;11:263–264. doi:10.1111/ddg.12002.
Yan T, Zhang Z. Adaptive and innate immune pathoge- nesis of bullous pemphigoid: a review. Front Immunol. 2023;14:1144429. doi:10.3389/fimmu.2023.1144429.
Li L, Huang Y, Xue R, Li G, Li L, Liang L, Lai K, Huang X, Qin Y, Zheng Y. T cell-mediated mechanisms of immune-related adverse events induced by immune check- point inhibitors. Crit Rev Oncol Hematol. 2025;213:104808. doi:10.1016/j.critrevonc.2025.104808.
Zhao CY, Hwang SJE, Consuegra G, Chou S, Fernandez- Peñas P. Anti-programmed cell death-1 therapy– associated bullous disorders: a systematic review of the literature. Melanoma Res. 2018;28:491–501. doi:10.1097/CMR.0000000000000500.
Carlos G, Anforth R, Chou S, Clements A, Fernandez-Peñas
P. A case of bullous pemphigoid in a patient with metasta- tic melanoma treated with pembrolizumab. Melanoma Res. 2015;25:265–268. doi:10.1097/CMR.0000000000000155.
Izumi K, Nishie W, Mai Y, Iwata H, Yamagami J, Shimizu
H. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol. 2016;136(11):2201–2210. doi:10.1016/j.jid.2016.06.622.
Tsiogka A, Bauer JW, Patsatsi A. Bullous pemphigoid as- sociated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature. Acta Derm Venereol. 2021;101:adv00377. doi:10.2340/00015555-3740.
García-Díez I, España A, Iranzo P. Epitope-spreading phe- nomena in dipeptidyl peptidase-4 inhibitor-associated bu- llous pemphigoid. Br J Dermatol. 2019;180:1262–1270. doi:10.1111/bjd.17690.
Gandarillas S, Dasgeb B. Enriched class II HLA inhe- rence in patients with checkpoint inhibitor-associated bu- llous pemphigoid. Int J Dermatol. 2025;64(2):399–401. doi:10.1111/ijd.17563.
Yancey KB. The pathophysiology of autoimmune blis- tering diseases. J Clin Invest. 2005;115(4):825–828. doi:10.1172/JCI24855.
Amber KT, Murrell DF. The role of eosinophils in bu- llous pemphigoid. Front Med (Lausanne). 2018;5:201. doi:10.3389/fmed.2018.00201.
Kridin K. Peripheral eosinophilia in bullous pemphigoid: pre- valence and influence on the clinical manifestation. Br J Der- matol. 2018;179(5):1141–1147. doi:10.1111/bjd.16679.
Garrido-Pérez PM, et al. Association of peripheral blood and cutaneous eosinophils with bullous pemphigoid severity and outcomes. Actas Dermosifiliogr. 2022;113(9):881–887. doi:10.1016/j.ad.2022.05.021.
Werth VP, Murrell DF, Joly P, et al. Pathophysiology of bu- llous pemphigoid: role of type 2 inflammation and emer- ging treatment strategies. Adv Ther. 2024;41:4418–4432. doi:10.1007/s12325-024-02992-w.
Guan S, Zhang L, Zhang J, Song W, Zhong D. A case report of refractory bullous pemphigoid induced by immune check- point inhibitor therapy. Front Immunol. 2023;13:1068978. doi:10.3389/fimmu.2022.1068978.
Natsuga K, Nishie W, Shinkuma S, et al. Antibo- dies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and - independent manner. J Immunol. 2012;188(11):5792–5799. doi:10.4049/jimmunol.1003402.
Iwata H, Ujiie H. Complement-independent blistering mechanisms in bullous pemphigoid. Exp Dermatol. 2017;26(12):1235–1239. doi:10.1111/exd.13367.
Zuo Y, Evangelista F, Culton D, et al. IgG4 au- toantibodies are inhibitory in the autoimmune disea- se bullous pemphigoid. J Autoimmun. 2016;73:111–119. doi:10.1016/j.jaut.2016.06.019.
Gresham LM, Kirchhof MG. A case of drug- induced bullous pemphigoid secondary to immu- notherapy treated with upadacitinib. SAGE Open Med Case Rep. 2023;11:2050313X231160926. doi:10.1177/2050313X231160926.
André T, Shiu KK, Kim TW, et al. Pembrolizu- mab in microsatellite-instability–high advanced colo- rectal cancer. N Engl J Med. 2020;383:2207–2218. doi:10.1056/NEJMoa2017699.
André T, Elez E, Van Cutsem E, et al. Nivolumab plus ipilimumab in microsatellite-instability–high metastatic co- lorectal cancer. N Engl J Med. 2024;391(21):2014–2026. doi:10.1056/NEJMoa2402141.
Mazumder A, Darji K, Smith K, Guo M. Two rare cases of bullous pemphigoid associated with immune checkpoint inhi- bitors. BMJ Case Rep. 2022;15:e253059. doi:10.1136/bcr- 2022-253059.
Pruessmann JN, Pruessmann W, Sadik CD. Immune check- point inhibitor–related autoimmune bullous dermatosis. J Dtsch Dermatol Ges. 2025. doi:10.1111/ddg.15638.
Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of bullous pemphigoid with immune check- point inhibitor therapy. JAMA Dermatol. 2022;158:933–941. doi:10.1001/jamadermatol.2022.1624.
Wang J, Hu X, Jiang W, et al. Clinical characteristics of pembrolizumab-induced bullous pemphigoid. Front Oncol. 2023;13:1095694. doi:10.3389/fonc.2023.1095694.
Béné J, Moulis G, Bennani I, et al. Bullous pemphi- goid and dipeptidyl peptidase IV inhibitors. Br J Dermatol. 2016;175(2):296–301. doi:10.1111/bjd.14601.
Tian R, Liang J, Li R, Zhou X. Acute kidney injury induced by immune checkpoint inhibitors. Kidney Dis. 2022;8:190–
201. doi:10.1159/000520798.
Hu Q, Hasuda H, Ueki K, et al. Reintroduction of nivo- lumab after acute interstitial nephritis. Int Cancer Conf J. 2020;9:127–132. doi:10.1007/s13691-020-00418-2.
Yang HH, Chang CW, Chen TD. Nivolumab-induced acute tubular injury. Clin Case Rep. 2023;11:e6991. doi:10.1002/ccr3.6991.
Koda R, Watanabe H, Tsuchida M, et al. Nivolumab- associated kidney injury. BMC Nephrol. 2018;19:48. doi:10.1186/s12882-018-0848-y.
Muddasani R, Talwar N, Mambetsariev I, et al. Immune checkpoint inhibitor nephritis. Cancer Immunol Immunother. 2024;73:200. doi:10.1007/s00262-024-03775-6.
Hamdan A-L, Abou Chaar J, Abou Rahal J. Laryngeal Manifestations of Bullous Pemphigoid: Case Report and Review of the Literature. Ear Nose Throat J. 2024 Feb 6. doi: 10.1177/01455613241230252. Online ahead of print.
Mima Y, Ohtsuka T, Ebato I, et al. Bullous pemphi- goid with CD4-positive T-cell infiltration during pembrolizumab. Diagnostics (Basel). 2024;14:1958. doi:10.3390/diagnostics14171958.
Earland N, Zhang W, Usmani A, et al. CD4 T cell and toxicity from immune checkpoint blockade. Immunol Rev. 2023;318:96–109. doi:10.1111/imr.13248.
Verheyden MJ, Bilgic A, Murrell DF. Drug-associated bu- llous pemphigoid. Acta Derm Venereol. 2020;100(15):5716. doi:10.2340/00015555-3457.
Wang X, Suppa M, Bruderer P, et al. Late derma- tologic presentation of bullous pemphigoid induced by anti-PD-1 therapy. Case Rep Oncol. 2021;14(2):861–867. doi:10.1159/000514806.
Guan S, Zhang L, Zhang J, Song W, Zhong D. Re- fractory bullous pemphigoid induced by immune check- point inhibitor therapy. Front Immunol. 2023;13:1068978. doi:10.3389/fimmu.2022.1068978.
Olsen E, Svoboda SA, Saikaly SK, Missall TA, Motaparthi
K. Delayed onset of bullous pemphigoid secondary to nivolu- mab. Cureus. 2023;15(8):e43230. doi:10.7759/cureus.43230.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Derechos de autor 2026 Jorge del Río Fernández, Verónica Velasco Durántez, Teresa González de la Hera, Adán Rodríguez González, Elena Sánchez Romero, Esmeralda Mateo Álvarez, Daniel Ruiz Sánchez, Virginia Galeazzi Martínez